1. Orjala, J., Oberlies, N. H., Pearce, C. J., Swanson, S. M. & Kinghorn, A. D. Discovery of potential anticancer agents from aquatic cyanobacteria, filamentous fungi, and tropical plants. in Bioactive Compounds from Natural Sources. Natural Products as Lead Compounds in Drug Discovery (ed. Tringali, C.) 37–63 2nd edn Taylor & Francis, London, UK, 2012.
2. Pearce, C., Eckard, P., Gruen-Wollny, I. & Hanske, F. G. Microorganisms: their role in the discovery and development of medicines. in Natural Product Chemistry for Drug Discovery (eds A. D. Buss & M. S. Butler) 215–244 The Royal Society of Chemistry, Cambridge, UK, 2010.
3. Fujita, T. et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. 47, 208–215 (1994).
4. Fujita, T. et al. Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyriocin, (2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-hydroxymethyleicos-6-enoic acid and structure-activity relationships of myriocin derivatives. J. Antibiot. 47, 216–224 (1994).
5. Strader, C. R., Pearce, C. J. & Oberlies, N. H. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J. Nat. Prod. 74, 900–907 (2011).